CIK 1791468
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2023-Q2. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 56.67% | 14 |
| Unclassified | 43.33% | 12 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | PLRX | PLIANT THERAPEUTICS, INC. | Health Care | 20.73% |
| 2 | REPARE THERAPEUTICS INC | Unclassified | 14.22% | |
| 3 | CGEM | Cullinan Therapeutics, Inc. | Health Care | 12.26% |
| 4 | ACELYRIN INC | Unclassified | 9.13% | |
| 5 | ORCHARD THERAPEUTICS PLC | Unclassified | 5.57% | |
| 6 | LRMR | Larimar Therapeutics, Inc. | Health Care | 5.35% |
| 7 | KROS | Keros Therapeutics, Inc. | Health Care | 5.15% |
| 8 | IKENA ONCOLOGY INC | Unclassified | 3.75% | |
| 9 | RARE | Ultragenyx Pharmaceutical Inc. | Health Care | 3.04% |
| 10 | CMPX | Compass Therapeutics, Inc. | Health Care | 2.21% |
14/26 names classified · sector 56.7% of weight · industry 56.7% · mkt cap 56.7%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 56.7% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/16 names) · unclassified 100.0%: , PLRX, CGEM, LRMR, KROS, RARE, CMPX, MLYS, SYRS, MLTX +6 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | PLRXPLIANT THERAPEUTICS INC | 3,014,199 | $52M | 20.7% | TRIM −3% |
| 2 | REPARE THERAPEUTICS INC | 2,966,674 | $36M | 14.2% | HOLD |
| 3 | CGEMCULLINAN THERAPEUTICS INC | 3,414,189 | $31M | 12.3% | HOLD |
| 4 | ACELYRIN INC | 2,262,990 | $23M | 9.1% | TRIM −15% |
| 5 | ORCHARD THERAPEUTICS PLC | 12,315,654 | $14M | 5.6% | ADD 1530% |
| 6 | LRMRLARIMAR THERAPEUTICS INC | 3,414,468 | $13M | 5.4% | HOLD |
| 7 | KROSKEROS THERAPEUTICS INC | 407,633 | $13M | 5.2% | HOLD |
| 8 | IKENA ONCOLOGY INC | 2,180,934 | $9M | 3.7% | ADD 3% |
| 9 | RAREULTRAGENYX PHARMACEUTICAL IN | 215,000 | $8M | 3.0% | ADD 153% |
| 10 | CMPXCOMPASS THERAPEUTICS INC | 2,829,712 | $6M | 2.2% | HOLD |
| 11 | MLYSMINERALYS THERAPEUTICS INC | 568,379 | $5M | 2.1% | NEW |
| 12 | INOZYME PHARMA INC | 1,270,027 | $5M | 2.1% | ADD 6% |
| 13 | SYRSSYROS PHARMACEUTICALS INC | 1,299,359 | $5M | 2.0% | ADD 69% |
| 14 | BLUEPRINT MEDICINES CORP | 92,888 | $5M | 1.9% | NEW |
| 15 | DIREXION SHS ETF TR | 225,000 | $5M | 1.8% | TRIM −31% |
| 16 | 2SEVENTY BIO INC | 1,002,007 | $4M | 1.6% | ADD 18% |
| 17 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 60,000 | $3M | 1.4% | NEW |
| 18 | OVIDOVID THERAPEUTICS INC | 864,822 | $3M | 1.3% | HOLD |
| 19 | SGMTSAGIMET BIOSCIENCES INC | 348,842 | $3M | 1.2% | NEW |
| 20 | OMEGA THERAPEUTICS INC | 1,055,882 | $2M | 0.9% | HOLD |
| 21 | BDTXBLACK DIAMOND THERAPEUTICS I | 720,000 | $2M | 0.8% | TRIM −4% |
| 22 | RLYBRALLYBIO CORP | 390,734 | $1M | 0.5% | TRIM −28% |
| 23 | IRONDISC MEDICINE INC | 25,000 | $1M | 0.5% | TRIM −80% |
| 24 | GRAPHITE BIO INC | 230,938 | $572,726 | 0.2% | HOLD |
| 25 | FREELINE THERAPEUTICS HLDGS | 86,654 | $372,613 | 0.1% | ADD 300% |
| 26 | DTILPRECISION BIOSCIENCES INC | 606,629 | $207,043 | 0.1% | TRIM −62% |
Where this firm's principals came from and which firms its alumni went on to found.
